Pulmonary Hypertension

This book is a clinical guide to controversial and emerging topics in pulmonary hypertension. There are multiple challenges and unanswered questions encountered by clinicians that evaluate, diagnose and treat patients with suspected or confirmed pulmonary vascular disease. This book provides a deep dive into the diagnosis and therapeutics of pulmonary hypertension supported by the literature and balanced with personal clinical experience. Expert authors have chosen these specific topics to address issues where uncertainty and/or controversy exists as well as highlight areas that are just being incorporated into clinical practice. These topics include: exercise pulmonary hypertension, sickle cell disease and pulmonary hypertension, and sarcoid pulmonary hypertension, among many others. Chapters address the diagnostic and treatment dilemmas posed by these various clinical entities through literature review, sharing of expert opinion, and review of recent guidelines and their applicability to the multiple different nuanced presentations of pulmonary hypertension. This is an ideal guide for pulmonologists, cardiologists, and other specialty practitioners caring for patients with pulmonary hypertension.

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

This book focuses on pulmonary arterial hypertension (PAH, Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) among the various groups of pulmonary hypertension (PH) whose classification was updated into five major categories at the 5th World Symposium held in Nice, France, in 2013. Readers will find recent progress, methods, and up-to-date information on PH mechanisms, diagnostic images, and treatment in the management of PH.This volume, with contributions by leading researchers worldwide in the field , consists of five parts, starting with the fundamentals of PH, then pathophysiology and genetics, treatment, and right ventricular function.

​This title will be presented as highly practical information on pharmaceutical options in pulmonary hypertension, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 100 and 150 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas.​

Detailing state-of-the-art developments in the various aspects of primary pulmonary hypertension (PPH), this practical reference explores the history, most current scientific concepts, and treatments of this disease. Includes new advances not yet formally published! Written by nearly 30 of the top international experts in the field, Primary Pulmonary Hypertension addresses the general histological features of the normal and hypertensive pulmonary vasculature and the pathology of PPH discusses etiological possibilities of pathogenesis, common morphological features, and findings in experimental models examines risks factors for PPH and looks separately at familial PPH and PPH in children presents an approach to the differential diagnosis of pulmonary hypertension, emphasizing the recognition of PPH elucidates the invasive and noninvasive modalities available for obtaining qualitative and quantitative hemodynamic data for the diagnosis of PPH covers a variety of therapeutic options and much more!

This volume focuses on current evidence-based pharmacological treatments of various forms of pulmonary hypertension and provides a comprehensive review of the latest developments in this area. The first part of the book covers the definition, classification, pathophysiology, pathology, biomarkers and animal models of the disease, thus laying the conceptual basis for what follows. The middle section provides an overview of the established therapies, such as calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and inhaled nitric oxide. The last section explores novel pathways and emerging therapeutic approaches including soluble guanylate cyclase stimulators, Rho-kinase inhibitors, inhibitors of serotonin receptors and transporters, peptide growth factors, vasoactive peptides, modulators of redox equilibrium and cyclic nucleotide homeostasis, as well as immunosuppressive and anti-proliferative agents. Particular attention is given to the clinical applications of these experimental therapies, that are on the horizon. The book thus spans the continuum from basic science to clinical applications.

An accessible reference text to help clinicians in all relevant specialties understand how to diagnose and manage the conditions of pulmonary hypertension and pulmonary areterial hypertension, including information on when and whom to refer patients to.

This open access book focuses on the molecular mechanism of congenital heart disease and pulmonary hypertension, offering new insights into the development of pulmonary circulation and the ductus arteriosus. It describes in detail the molecular mechanisms involved in the development and morphogenesis of the heart, lungs and ductus arteriosus, covering a range of topics such as gene functions, growth factors, transcription factors and cellular interactions, as well as stem cell engineering technologies. The book also presents recent advances in our understanding of the molecular mechanism of lung development, pulmonary hypertension and molecular regulation of the ductus arteriosus. As such, it is an ideal resource for physicians, scientists and investigators interested in the latest findings on the origins of congenital heart disease and potential future therapies involving pulmonary circulation/hypertension and the ductus arteriosus.